Business Wire

VIRTUOZZO

18.5.2021 10:02:05 CEST | Business Wire | Press release

Share
Virtuozzo Reveals New Hybrid Cloud Solution, Designed Specifically for Managed and Cloud Service Providers

Virtuozzo, a global leader in high-efficiency virtualization and hyperconverged software solutions, has announced the availability of its newest product, Virtuozzo Hybrid Cloud . The solution enables Managed Service Providers (MSPs) and Cloud Service Providers (CSP) to design, build and sell modern cloud services to customers quickly and more cost-effectively than traditional hyperscalers.

The cloud infrastructure market continues to experience strong growth as businesses become increasingly more dependent on cloud-based resources. This evolution presents an opportunity for service providers to carve out an alternative to the often complex and expensive traditional cloud providers. According to Liam Eagle, Research Director, 451 Research, a part of S&P Global Market Intelligence, “As the breadth of organizations seeking cloud solutions continues to grow, a gap in the skills necessary to navigate the complexities of the most advanced cloud platforms is a common limitation. This presents an opportunity for the alternative vendors to solidify the role of their services as delivering the core value proposition of cloud in a simpler, more digestible and often lower-cost configuration.” 1

Virtuozzo Hybrid Cloud was created to help service providers address this demand. The company’s new product offers MSPs and CSPs an alternative, fully managed cloud solution that ensures clear SLAs and 24/7 production support, allowing service providers to focus on value-added services and project development rather than infrastructure maintenance and management.

Virtuozzo Hybrid Cloud is one of the only hybrid cloud solutions exclusively for MSPs and CSPs. It offers Infrastructure as a Service (IaaS), Platform as a Service (PaaS), Load Balancer as a Service (LBaaS), Storage as a Service (SaaS), and other cloud services in multiple locations worldwide.

Service providers can buy cloud resources directly from Virtuozzo by connecting any Open Stack compatible cloud management platform such as CloudBlue Connect, HostBill, WHMCS, Fleio, or from Virtuozzo Hybrid Cloud distributors.

“Over the past year and a half, we have seen a lot of demand from our existing service provider partners for a solution that enables them to offer infrastructure solutions. We designed Virtuozzo Hybrid Cloud to address this need while offering more than 30% savings over comparable solutions. We are thrilled to bring a turnkey solution to the market that helps MSPs and CSPs open new opportunities and drive customer growth for years to come. We are excited to innovate and grow together with our partners,” remarks Ahmed Amni, Director of Sales, EMEA.

Virtuozzo Hybrid Cloud is built on Virtuozzo Hybrid Infrastructure, a best-in-class hyperconverged infrastructure (HCI) solution. Virtuozzo Hybrid Infrastructure provides service providers with cost-effective, easy-to-manage hyperconverged infrastructure that optimizes hardware utilization, lowers total cost of ownership, and delivers high server performance and availability. Secure by design, Virtuozzo Hybrid Infrastructure combines compute, storage, and networking services with advanced analytics and monitoring in a single, hardware-agnostic solution.

Virtuozzo Hybrid Cloud is available to service providers throughout Europe today, with global availability rolling out quickly. Pricing is based on either a Pay-as-You-Go model or on a reservation-based model, which extends additional cost savings to partners. To learn more about partnership opportunities or to view a product demo visit the company’s website .

About Virtuozzo

Virtuozzo is a leading, global provider of hybrid virtualization, storage and cloud enablement software solutions. The company’s software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the opensource community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU and the Linux kernel. Learn more www.virtuozzo.com .

1 451 Research, Demand and opportunity in the alternative cloud provider market , January 2021

Link:

ClickThru

Social Media:

https://www.facebook.com/VirtuozzoInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye